Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies ⁎ ⁎ Results of study SP630 were partially presented at the 58th Annual Meeting of the American Academy of Neurology, San Diego, California, April 1–8, 2006, and at the 9th Congress of the European Federation of the Neurological Science, Athens, Greece, September 17–20, 2006.
作者: Jan-Peer ElshoffMarina BraunJens-Otto AndreasMichelle MiddleWilli Cawello
作者单位: 1UCB Pharma, Monheim am Rhein, Germany
2QdotPharma Early Phase Clinical Unit, George, South Africa
刊名: Clinical Therapeutics, 2012, Vol.34 (4), pp.966-978
来源数据库: Elsevier Journal
DOI: 10.1016/j.clinthera.2012.02.008
关键词: application sitebioavailabilitycontinuous 24-hour drug deliverydose proportionalityrotigotine transdermal patchsteady-state pharmacokinetic profile
原始语种摘要: Abstract(#br)Background(#br)The dopamine agonist rotigotine is formulated in a transdermal delivery system (patch) for once-daily application. It has been reported as efficacious in the treatment of idiopathic Parkinson's disease (PD) and restless legs syndrome.(#br)Objective(#br)This article summarizes the results of 3 clinical studies conducted to characterize the 24-hour pharmacokinetic profile of rotigotine in steady state and the effect of different patch application sites on this profile. In addition, the relative bioavailability of a single, large patch versus 2 smaller patches was assessed.(#br)Methods(#br)One Phase I study (SP871) assessed the steady-state pharmacokinetic properties at different application sites at a rotigotine maintenance dose of 3 mg/24 hours in healthy...
全文获取路径: Elsevier  (合作)
影响因子:2.23 (2012)

  • transdermal 穿过表皮的
  • Greece 希腊
  • steady 稳定的
  • state 状态
  • profile 纵断图
  • shoulder 肩膀儿
  • concentrations 浓聚物
  • application 申请
  • delivery 移交
  • efficacious 有效